• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用参数化g公式通过观察性数据复制随机试验结果:在血液透析患者静脉铁治疗中的应用

Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients.

作者信息

Karaboyas Angelo, Morgenstern Hal, Fleischer Nancy L, Schaubel Douglas E, Robinson Bruce M

机构信息

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

University of Michigan, Department of Epidemiology, Ann Arbor, MI, USA.

出版信息

Clin Epidemiol. 2020 Nov 11;12:1249-1260. doi: 10.2147/CLEP.S283321. eCollection 2020.

DOI:10.2147/CLEP.S283321
PMID:33204166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7667704/
Abstract

BACKGROUND

Reproducibility of clinical and epidemiologic research is important to generalize findings and has increasingly been scrutinized. A recently published randomized trial, PIVOTAL, evaluated high vs low intravenous iron dosing strategies to manage anemia in hemodialysis patients in the UK. Our objective was to assess the reproducibility of the PIVOTAL trial findings using data from a well-established cohort study, the Dialysis Outcomes and Practice Patterns Study (DOPPS).

METHODS

To overcome the absence of randomization in the DOPPS, we applied the parametric g-formula, an extension of standardization to longitudinal data. We estimated the effect of a proactive high-dose vs reactive low-dose iron supplementation strategy on all-cause mortality (primary outcome), hemoglobin, two measures of iron concentration (ferritin and TSAT), and erythropoiesis-stimulating agent dose over 12 months of follow-up in 6325 DOPPS patients.

RESULTS

Comparing high- vs low-iron dose strategies, the 1-year mortality risk difference was 0.020 (95% CI: 0.008, 0.031) and risk ratio was 1.20 (95% CI: 1.07, 1.33), compared with null 1-year findings in the PIVOTAL trial. Differences in secondary outcomes were directionally consistent but of lesser magnitude than in the PIVOTAL trial.

CONCLUSION

Our findings are somewhat consistent with the recent PIVOTAL trial, with discrepancies potentially attributable to model misspecification and differences between the two study populations. In addition to the importance of our results to nephrologists and hence hemodialysis patients, our analysis illustrates the utility of the parametric g-formula for generalizing results and comparing complex and dynamic treatment strategies using observational data.

摘要

背景

临床和流行病学研究的可重复性对于推广研究结果很重要,并且越来越受到严格审查。最近发表的一项随机试验PIVOTAL评估了高剂量与低剂量静脉注射铁剂策略对英国血液透析患者贫血的治疗效果。我们的目的是使用一项成熟的队列研究——透析结果和实践模式研究(DOPPS)的数据,评估PIVOTAL试验结果的可重复性。

方法

为了克服DOPPS中缺乏随机分组的问题,我们应用了参数化g公式,这是一种将标准化扩展到纵向数据的方法。我们估计了在6325名DOPPS患者中,前瞻性高剂量与反应性低剂量铁补充策略对全因死亡率(主要结局)、血红蛋白、两种铁浓度指标(铁蛋白和转铁蛋白饱和度)以及促红细胞生成素剂量在12个月随访期内的影响。

结果

比较高剂量与低剂量铁剂策略,1年死亡率风险差异为0.020(95%置信区间:0.008,0.031),风险比为1.20(95%置信区间:1.07,1.33),而PIVOTAL试验的1年结果为零差异。次要结局的差异在方向上一致,但幅度小于PIVOTAL试验。

结论

我们的研究结果与最近的PIVOTAL试验有些一致,差异可能归因于模型设定错误以及两个研究人群之间的差异。除了我们的结果对肾病学家以及因此对血液透析患者的重要性外,我们的分析还说明了参数化g公式在推广结果以及使用观察性数据比较复杂和动态治疗策略方面的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/9bb1ffc72d25/CLEP-12-1249-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/d6c6256831a6/CLEP-12-1249-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/76b6cae52fdc/CLEP-12-1249-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/04c81a6d6bb4/CLEP-12-1249-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/9bb1ffc72d25/CLEP-12-1249-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/d6c6256831a6/CLEP-12-1249-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/76b6cae52fdc/CLEP-12-1249-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/04c81a6d6bb4/CLEP-12-1249-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a923/7667704/9bb1ffc72d25/CLEP-12-1249-g0004.jpg

相似文献

1
Replicating Randomized Trial Results with Observational Data Using the Parametric g-Formula: An Application to Intravenous Iron Treatment in Hemodialysis Patients.使用参数化g公式通过观察性数据复制随机试验结果:在血液透析患者静脉铁治疗中的应用
Clin Epidemiol. 2020 Nov 11;12:1249-1260. doi: 10.2147/CLEP.S283321. eCollection 2020.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.血液透析中调整静脉铁剂剂量的目标:一项概念验证研究。
BMC Nephrol. 2017 Mar 20;18(1):97. doi: 10.1186/s12882-017-0513-x.
4
Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).评估静脉注射铁剂剂量在常见临床实践中治疗贫血的有效性:透析预后与实践模式研究(DOPPS)的结果
BMC Nephrol. 2017 Nov 9;18(1):330. doi: 10.1186/s12882-017-0745-9.
5
6
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.维持性血液透析患者的静脉铁剂治疗。
N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26.
7
Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.透析患者不同静脉铁剂策略随机分组的卒中:来自 PIVOTAL 试验的预设分析。
Kidney360. 2021 Sep 16;2(11):1761-1769. doi: 10.34067/KID.0004272021. eCollection 2021 Nov 25.
8
Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.两种不同临床策略对实现肾脏贫血 KDIGO 目标的影响——一项欧洲血液透析多中心分析。
BMC Nephrol. 2019 Jan 7;20(1):5. doi: 10.1186/s12882-018-1196-7.
9
Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study.台湾进行常规血液透析患者的贫血和铁参数与死亡率的关系:AIM-HD 研究。
J Am Heart Assoc. 2018 Aug 7;7(15):e009206. doi: 10.1161/JAHA.118.009206.
10
Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.接受血液透析患者的铁剂和红细胞生成刺激剂剂量对健康相关生活质量的比较效果。
Am J Kidney Dis. 2016 Feb;67(2):271-82. doi: 10.1053/j.ajkd.2015.09.011. Epub 2015 Oct 23.

引用本文的文献

1
Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review.旨在模拟随机试验的观察性研究报告:系统评价。
JAMA Netw Open. 2023 Sep 5;6(9):e2336023. doi: 10.1001/jamanetworkopen.2023.36023.
2
Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database.避免时间相关偏差:一项关于抗糖尿病药物与胰腺癌的可行性研究,将参数化g公式应用于大型德国医疗数据库
Clin Epidemiol. 2021 Oct 28;13:1027-1038. doi: 10.2147/CLEP.S328342. eCollection 2021.

本文引用的文献

1
A manifesto for reproducible science.可重复科学宣言。
Nat Hum Behav. 2017 Jan 10;1(1):0021. doi: 10.1038/s41562-016-0021.
2
Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS.估算可归因于潜在可改变风险因素的首年血液透析死亡比例:透析预后与实践模式研究(DOPPS)结果
Clin Epidemiol. 2020 Jan 16;12:51-60. doi: 10.2147/CLEP.S233197. eCollection 2020.
3
Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence.利用真实世界数据复制临床试验证据的可行性。
JAMA Netw Open. 2019 Oct 2;2(10):e1912869. doi: 10.1001/jamanetworkopen.2019.12869.
4
Post-PIVOTAL Iron Dosing with Maintenance Hemodialysis.维持性血液透析的关键期后铁剂给药
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1533-1535. doi: 10.2215/CJN.02300219. Epub 2019 Jun 10.
5
Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples.随机试验和观察性研究中的效应估计:将苹果与苹果进行比较。
Am J Epidemiol. 2019 Aug 1;188(8):1569-1577. doi: 10.1093/aje/kwz100.
6
Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients.血液透析患者动态静脉铁剂给药策略的安全性。
Clin J Am Soc Nephrol. 2019 May 7;14(5):728-737. doi: 10.2215/CJN.03970318. Epub 2019 Apr 15.
7
US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States.美国肾脏数据系统2018年年报:美国肾脏疾病流行病学
Am J Kidney Dis. 2019 Mar;73(3 Suppl 1):A7-A8. doi: 10.1053/j.ajkd.2019.01.001. Epub 2019 Feb 21.
8
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.维持性血液透析患者的静脉铁剂治疗。
N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26.
9
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.随机对照试验比较前瞻性、高剂量与反应性、低剂量静脉铁补充在血液透析中的作用(关键):研究设计和基线数据。
Am J Nephrol. 2018;48(4):260-268. doi: 10.1159/000493551. Epub 2018 Oct 10.
10
Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study.血清铁蛋白与死亡率的关联:来自美国、日本和欧洲透析结局和实践模式研究的发现。
Nephrol Dial Transplant. 2018 Dec 1;33(12):2234-2244. doi: 10.1093/ndt/gfy190.